Thomas Eschenhagen

Summary

Affiliation: University Medical Center Hamburg-Eppendorf
Country: Germany

Publications

  1. pmc Increased myocardial SERCA expression in early type 2 diabetes mellitus is insulin dependent: In vivo and in vitro data
    Sabine Fredersdorf
    Klinik und Poliklinik fur Innere Medizin II, Universitat Regensburg, Regensburg, Germany
    Cardiovasc Diabetol 11:57. 2012
  2. pmc Increased afterload induces pathological cardiac hypertrophy: a new in vitro model
    Marc N Hirt
    Department of Experimental Pharmacology and Toxicology, University Medical Center Hamburg Eppendorf and DZHK, Germany
    Basic Res Cardiol 107:307. 2012
  3. doi request reprint [Personalized therapy in cardiology. Biomarkers, pharmacogenetics and therapy of monogenic diseases]
    T Eschenhagen
    Institut für Experimentelle Pharmakologie und Toxikologie, Universitatsklinikum Hamburg Eppendorf, Martinistr 52, 20246, Hamburg
    Internist (Berl) 54:147-8, 150-2, 154. 2013
  4. doi request reprint Physiological aspects of cardiac tissue engineering
    Thomas Eschenhagen
    Department of Experimental Pharmacology and Toxicology, Cardiovascular Research Center Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Am J Physiol Heart Circ Physiol 303:H133-43. 2012
  5. pmc Is ryanodine receptor phosphorylation key to the fight or flight response and heart failure?
    Thomas Eschenhagen
    Department of Experimental Pharmacology and Toxicology, Cardiovascular Research Center Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    J Clin Invest 120:4197-203. 2010
  6. doi request reprint Impact of ANKRD1 mutations associated with hypertrophic cardiomyopathy on contraction parameters of engineered heart tissue
    Claudia Crocini
    Department of Experimental Pharmacology and Toxicology, Cardiovascular Research Center, University Medical Center Hamburg Eppendorf, Martinistrase 52, 20246, Hamburg, Germany
    Basic Res Cardiol 108:349. 2013
  7. doi request reprint Phosphatase inhibitor-1-deficient mice are protected from catecholamine-induced arrhythmias and myocardial hypertrophy
    Ali El-Armouche
    Institute of Experimental and Clinical Pharmacology and Toxicology, University Medical Center Hamburg Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany
    Cardiovasc Res 80:396-406. 2008
  8. doi request reprint Treatment with atorvastatin partially protects the rat heart from harmful catecholamine effects
    Ariane Schmechel
    Department of Experimental and Clinical Pharmacology, University Medical Center Hamburg Eppendorf, Martinistr 52, 20246 Hamburg, Germany
    Cardiovasc Res 82:100-6. 2009
  9. doi request reprint Mechanical unloading of the rat heart involves marked changes in the protein kinase-phosphatase balance
    Alexander P Schwoerer
    Department of Vegetative Physiology and Pathophysiology, University Medical Center Hamburg Eppendorf, Germany
    J Mol Cell Cardiol 45:846-52. 2008
  10. ncbi request reprint Adenovirus-delivered short hairpin RNA targeting PKCalpha improves contractile function in reconstituted heart tissue
    Ali El-Armouche
    Institute of Experimental and Clinical Pharmacology and Toxicology, University Medical Center Hamburg Eppendorf, Hamburg, D 20246, Germany
    J Mol Cell Cardiol 43:371-6. 2007

Detail Information

Publications49

  1. pmc Increased myocardial SERCA expression in early type 2 diabetes mellitus is insulin dependent: In vivo and in vitro data
    Sabine Fredersdorf
    Klinik und Poliklinik fur Innere Medizin II, Universitat Regensburg, Regensburg, Germany
    Cardiovasc Diabetol 11:57. 2012
    ..Calcium (Ca2+) handling proteins are known to play a pivotal role in the pathophysiology of cardiomyopathy. However little is known about early changes in the diabetic heart and the impact of insulin treatment (Ins)...
  2. pmc Increased afterload induces pathological cardiac hypertrophy: a new in vitro model
    Marc N Hirt
    Department of Experimental Pharmacology and Toxicology, University Medical Center Hamburg Eppendorf and DZHK, Germany
    Basic Res Cardiol 107:307. 2012
    ..The model will be useful to investigate novel therapeutic approaches in a simple and fast manner...
  3. doi request reprint [Personalized therapy in cardiology. Biomarkers, pharmacogenetics and therapy of monogenic diseases]
    T Eschenhagen
    Institut für Experimentelle Pharmakologie und Toxikologie, Universitatsklinikum Hamburg Eppendorf, Martinistr 52, 20246, Hamburg
    Internist (Berl) 54:147-8, 150-2, 154. 2013
    ..Taken together personalized approaches will gain importance in the cardiovascular field but this requires the development of better methods and research that quantifies the true value of the new knowledge...
  4. doi request reprint Physiological aspects of cardiac tissue engineering
    Thomas Eschenhagen
    Department of Experimental Pharmacology and Toxicology, Cardiovascular Research Center Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Am J Physiol Heart Circ Physiol 303:H133-43. 2012
    ..This review summarizes current tissue engineering techniques with their strengths and limitations and possible future applications...
  5. pmc Is ryanodine receptor phosphorylation key to the fight or flight response and heart failure?
    Thomas Eschenhagen
    Department of Experimental Pharmacology and Toxicology, Cardiovascular Research Center Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    J Clin Invest 120:4197-203. 2010
    ..Moreover, the experiments revealed an influence of redox modifications of RyR2 that may account for some discrepancies in the field...
  6. doi request reprint Impact of ANKRD1 mutations associated with hypertrophic cardiomyopathy on contraction parameters of engineered heart tissue
    Claudia Crocini
    Department of Experimental Pharmacology and Toxicology, Cardiovascular Research Center, University Medical Center Hamburg Eppendorf, Martinistrase 52, 20246, Hamburg, Germany
    Basic Res Cardiol 108:349. 2013
    ....
  7. doi request reprint Phosphatase inhibitor-1-deficient mice are protected from catecholamine-induced arrhythmias and myocardial hypertrophy
    Ali El-Armouche
    Institute of Experimental and Clinical Pharmacology and Toxicology, University Medical Center Hamburg Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany
    Cardiovasc Res 80:396-406. 2008
    ..I-1 is downregulated in failing hearts and thus contributes to beta-adrenergic desensitization. It is unclear whether this should be viewed as a predominantly adverse or protective response...
  8. doi request reprint Treatment with atorvastatin partially protects the rat heart from harmful catecholamine effects
    Ariane Schmechel
    Department of Experimental and Clinical Pharmacology, University Medical Center Hamburg Eppendorf, Martinistr 52, 20246 Hamburg, Germany
    Cardiovasc Res 82:100-6. 2009
    ..We examined whether atorvastatin exerts similar effects in vivo and protects the rat heart from harmful effects of catecholamines...
  9. doi request reprint Mechanical unloading of the rat heart involves marked changes in the protein kinase-phosphatase balance
    Alexander P Schwoerer
    Department of Vegetative Physiology and Pathophysiology, University Medical Center Hamburg Eppendorf, Germany
    J Mol Cell Cardiol 45:846-52. 2008
    ..This shift may also contribute to the reduction in phosphorylation levels of cardiac phosphoproteins observed in diseased human hearts after LVAD...
  10. ncbi request reprint Adenovirus-delivered short hairpin RNA targeting PKCalpha improves contractile function in reconstituted heart tissue
    Ali El-Armouche
    Institute of Experimental and Clinical Pharmacology and Toxicology, University Medical Center Hamburg Eppendorf, Hamburg, D 20246, Germany
    J Mol Cell Cardiol 43:371-6. 2007
    ..The data support a role of PKCalpha as a negative regulator of myocardial contractility and demonstrate that EHTs in conjunction with AV-delivered shRNA are a useful model for target validation...
  11. doi request reprint Adrenergic stress reveals septal hypertrophy and proteasome impairment in heterozygous Mybpc3-targeted knock-in mice
    Saskia Schlossarek
    Department of Experimental Pharmacology and Toxicology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    J Muscle Res Cell Motil 33:5-15. 2012
    ..This supports the hypothesis that proteasome impairment contributes to the pathophysiology of HCM...
  12. pmc Constitutively active phosphatase inhibitor-1 improves cardiac contractility in young mice but is deleterious after catecholaminergic stress and with aging
    Katrin Wittköpper
    Institute of Experimental and Clinical Pharmacology and Toxicology, Cardiovascular Research Center Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    J Clin Invest 120:617-26. 2010
    ..These data should be considered in the development of novel therapies for heart failure...
  13. doi request reprint Unloaded rat hearts in vivo express a hypertrophic phenotype of cardiac repolarization
    Alexander Peter Schwoerer
    Institut für Vegetative Physiologie und Pathophysiologie, Universitatsklinikum Hamburg Eppendorf, Germany
    J Mol Cell Cardiol 45:633-41. 2008
    ..This indicates that unloaded rat hearts in vivo express a hypertrophic phenotype of cardiac repolarization at the cellular and the molecular level...
  14. ncbi request reprint Development of a biological ventricular assist device: preliminary data from a small animal model
    Yalin Yildirim
    Institute of Experimental and Clinical Pharmacology and Toxicology, University Medical Center Hamburg Eppendorf, Martinistr 52, 20246 Hamburg, Germany
    Circulation 116:I16-23. 2007
    ..Here, we hypothesized that pouch-like heart muscle constructs can be generated by using a novel EHT-casting technology and applied as heart-embracing cardiac grafts in vivo...
  15. pmc Human engineered heart tissue as a versatile tool in basic research and preclinical toxicology
    Sebastian Schaaf
    Department of Experimental Pharmacology and Toxicology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    PLoS ONE 6:e26397. 2011
    ..In conclusion this study establishes hEHT as a simple in vitro model for heart research...
  16. ncbi request reprint Heart muscle engineering: an update on cardiac muscle replacement therapy
    Wolfram Hubertus Zimmermann
    Institute of Experimental and Clinical Pharmacology and Toxicology, University Medical Center Hamburg Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany
    Cardiovasc Res 71:419-29. 2006
    ..We also touch on legal and economic aspects that have to be considered before engineered myocardium may eventually be applied in patients and discuss who may be a potential recipient...
  17. ncbi request reprint Cardiac myosin-binding protein C is required for complete relaxation in intact myocytes
    Lutz Pohlmann
    Institute of Experimental and Clinical Pharmacology and Toxicology, University Medical Center Hamburg Eppendorf, D 20246 Hamburg, Germany
    Circ Res 101:928-38. 2007
    ..Our findings indicate that cMyBP-C functions as a restraint on myosin-actin interaction at low Ca2+ and short SL to allow complete relaxation during diastole...
  18. ncbi request reprint Optimizing engineered heart tissue for therapeutic applications as surrogate heart muscle
    Hiroshi Naito
    Institute of Experimental and Clinical Pharmacology and Toxicology, University Medical Center Hamburg Eppendorf, Martinistr 5, 20246 Hamburg, Germany
    Circulation 114:I72-8. 2006
    ....
  19. doi request reprint Atrogin-1 and MuRF1 regulate cardiac MyBP-C levels via different mechanisms
    Giulia Mearini
    Institute of Experimental and Clinical Pharmacology and Toxicology, University Medical Center Hamburg Eppendorf, Martinistrasse 52, D 20246 Hamburg, Germany
    Cardiovasc Res 85:357-66. 2010
    ..Since the diversity and specificity of UPS regulation lie in E3 ubiquitin ligases, we investigated whether the muscle-specific E3 ligases atrogin-1 or muscle ring finger protein-1 (MuRF1) mediate degradation of truncated cMyBP-C...
  20. ncbi request reprint Role of calcineurin and protein phosphatase-2A in the regulation of phosphatase inhibitor-1 in cardiac myocytes
    Ali El-Armouche
    Institute of Experimental and Clinical Pharmacology, Medical Center Hamburg Eppendorf, Hamburg, Germany
    Biochem Biophys Res Commun 346:700-6. 2006
    ..The results indicate that calcineurin and PP2A act to maintain a low basal level of phosphorylated (active) I-1 in living cardiac myocytes. Calcineurin may constitute a cross-talk between calcium- and cAMP-dependent pathways...
  21. ncbi request reprint Decreased phosphorylation levels of cardiac myosin-binding protein-C in human and experimental heart failure
    Ali El-Armouche
    Institute of Experimental and Clinical Pharmacology and Toxicology, University Medical Center Hamburg Eppendorf, Hamburg, D 20246, Germany
    J Mol Cell Cardiol 43:223-9. 2007
    ..Thus, the compromised contractile function of the failing heart might be in part attributable to reduced cMyBP-C phosphorylation levels...
  22. doi request reprint Localization of Islet-1-positive cells in the healthy and infarcted adult murine heart
    Florian Weinberger
    Department of Experimental Pharmacology and Toxicology, Cardiovascular Research Center, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Circ Res 110:1303-10. 2012
    ..Objective: We investigated the distribution and identity of Islet-1(+) cells in adult murine heart and evaluated whether their number or distribution change with age or after myocardial infarction...
  23. doi request reprint A novel genetic variant in the transcription factor Islet-1 exerts gain of function on myocyte enhancer factor 2C promoter activity
    Felix W Friedrich
    Department of Experimental Pharmacology and Toxicology, Cardiovascular Research Center, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Eur J Heart Fail 15:267-76. 2013
    ..In this study we evaluated whether ISL1 variants are associated with hypertrophic (HCM), dilated (DCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), or with Emery-Dreifuss muscular dystrophy (EDMD)...
  24. pmc Rescue of cardiomyopathy through U7snRNA-mediated exon skipping in Mybpc3-targeted knock-in mice
    Christina Gedicke-Hornung
    Department of Experimental Pharmacology and Toxicology, Cardiovascular Research Center, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    EMBO Mol Med 5:1060-77. 2013
    ..Although the therapeutic effect was transient and therefore requires optimization to be maintained over an extended period, this proof-of-concept study paves the way towards a causal therapy of HCM. ..
  25. doi request reprint Development of a drug screening platform based on engineered heart tissue
    Arne Hansen
    Department of Experimental and Clinical Pharmacology and Toxicology, Cardiovascular Research Center, University Medical Center Hamburg Eppendorf, Germany
    Circ Res 107:35-44. 2010
    ..Objective: Here, we present a new miniaturized and automated method based on engineered heart tissue (EHT)...
  26. pmc The MLCK-mediated alpha1-adrenergic inotropic effect in atrial myocardium is negatively modulated by PKCepsilon signaling
    Michael Grimm
    Institute of Experimental and Clinical Pharmacology and Toxicology, University Medical Center, Hamburg, Germany
    Br J Pharmacol 148:991-1000. 2006
    ....
  27. doi request reprint Defective proteolytic systems in Mybpc3-targeted mice with cardiac hypertrophy
    Saskia Schlossarek
    Department of Experimental Pharmacology and Toxicology, Cardiovascular Research Center, University Medical Center Hamburg Eppendorf, Martinistrase 52, 20246, Hamburg, Germany
    Basic Res Cardiol 107:235. 2012
    ....
  28. doi request reprint The ubiquitin-proteasome system and nonsense-mediated mRNA decay in hypertrophic cardiomyopathy
    Lucie Carrier
    Institute of Experimental and Clinical Pharmacology and Toxicology, Cardiovascular Research Center, University Medical Center Hamburg Eppendorf, Martinistrasse 52, D 20246 Hamburg, Germany
    Cardiovasc Res 85:330-8. 2010
    ..This review discusses clinical and genetic aspects of HCM and the role of NMD and UPS in the regulation of mutant proteins, evidence for impairment of UPS as a pathogenic factor, as well as potential therapies for HCM...
  29. ncbi request reprint Reduced contractile response to alpha1-adrenergic stimulation in atria from mice with chronic cardiac calmodulin kinase II inhibition
    Michael Grimm
    Institute of Experimental and Clinical Pharmacology and Toxicology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    J Mol Cell Cardiol 42:643-52. 2007
    ..Our data indicate a role of CaMKII in post-rest potentiation and the positive inotropic effect of alpha-adrenergic stimulation at low frequencies...
  30. doi request reprint Progesterone receptor variants associated with the PROGINS haplotype exhibit functional properties similar to those of wild-type progesterone receptor
    Justus Stenzig
    Institute of Experimental and Clinical Pharmacology and Toxicology, University Medical Center Hamburg Eppendorf, Martinistrasse, Hamburg, Germany
    Pharmacogenet Genomics 22:629-41. 2012
    ..Our study aimed at elucidating the functional consequences of the PROGINS-associated single nucleotide polymorphisms of PRA and PRB (i.e. Thr344 and Leu660) as compared with wild-type PR (Ser344, Val660)...
  31. ncbi request reprint Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts
    Wolfram Hubertus Zimmermann
    Institute of Experimental and Clinical Pharmacology, University Medical Center Hamburg Eppendorf, Germany
    Nat Med 12:452-8. 2006
    ..Thus, our study provides evidence that large contractile cardiac tissue grafts can be constructed in vitro, can survive after implantation and can support contractile function of infarcted hearts...
  32. doi request reprint Cardiac tissue engineering: a clinical perspective
    Wolfram Hubertus Zimmermann
    Institute of Experimental and Clinical Pharmacology and Toxicology, University Medical Center Hamburg Eppendorf, Germany
    Future Cardiol 3:435-45. 2007
    ....
  33. ncbi request reprint Embryonic stem cells for cardiac muscle engineering
    Wolfram Hubertus Zimmermann
    Institute of Experimental and Clinical Pharmacology, University Medical Center Hamburg Eppendorf, 20246 Hamburg, Germany
    Trends Cardiovasc Med 17:134-40. 2007
    ..This review discusses the usefulness of ES cells in cardiac tissue engineering and alternative, embryo-sparing technologies to derive ES cells...
  34. doi request reprint Beta-adrenergic stimulation and myocardial function in the failing heart
    Ali El-Armouche
    Department of Experimental and Clinical Pharmacology and Toxicology, University Medical Center Hamburg Eppendorf, Germany
    Heart Fail Rev 14:225-41. 2009
    ..Which lessons can be drawn from studies in genetically engineered mice, which from (pharmaco) genetic studies? Finally, what are promising targets downstream of beta-adrenergic receptors that go beyond the current neurohumoral blockade?..
  35. pmc Repair of Mybpc3 mRNA by 5'-trans-splicing in a Mouse Model of Hypertrophic Cardiomyopathy
    Giulia Mearini
    1 Department of Experimental Pharmacology and Toxicology, Cardiovascular Research Center, University Medical Center Hamburg Eppendorf, Hamburg, Germany 2 DZHK German Centre for Cardiovascular Research, partner site Hamburg Kiel Lübeck, Hamburg, Germany
    Mol Ther Nucleic Acids 2:e102. 2013
    ..Molecular Therapy-Nucleic Acids (2013) 2, e102; doi:10.1038/mtna.2013.31; published online 2 July 2013. ..
  36. ncbi request reprint Ouabain treatment is associated with upregulation of phosphatase inhibitor-1 and Na+/Ca(2+)-exchanger and beta-adrenergic sensitization in rat hearts
    Ali El-Armouche
    Institute of Experimental and Clinical Pharmacology, University Hospital Eppendorf, Hamburg, Germany
    Biochem Biophys Res Commun 318:219-26. 2004
    ....
  37. pmc Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation
    Volker Rudolph
    1Department of General and Interventional Cardiology and Cardiovascular Research Center, University Heart Center, Hamburg, Germany
    Nat Med 16:470-4. 2010
    ..Our data demonstrate that MPO is a crucial prerequisite for structural remodeling of the myocardium, leading to an increased vulnerability to atrial fibrillation...
  38. doi request reprint Evidence for FHL1 as a novel disease gene for isolated hypertrophic cardiomyopathy
    Felix W Friedrich
    Department of Experimental Pharmacology and Toxicology, Cardiovascular Research Center, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Hum Mol Genet 21:3237-54. 2012
    ..These data, together with previous findings of proteasome impairment in HCM, suggest that FHL1 mutant proteins may act as poison peptides, leading to hypertrophy, diastolic dysfunction and/or altered contractility, all features of HCM...
  39. doi request reprint Nonsense-mediated mRNA decay and ubiquitin-proteasome system regulate cardiac myosin-binding protein C mutant levels in cardiomyopathic mice
    Nicolas Vignier
    Institute of Experimental and Clinical Pharmacology and Toxicology, University Medical Center Hamburg Eppendorf, Martinistrasse 52, D 20246 Hamburg, Germany
    Circ Res 105:239-48. 2009
    ..Mutations in the MYBPC3 gene encoding cardiac myosin-binding protein (cMyBP)-C are frequent causes of hypertrophic cardiomyopathy, but the mechanisms leading from mutations to disease remain elusive...
  40. doi request reprint A new polymorphism in human calmodulin III gene promoter is a potential modifier gene for familial hypertrophic cardiomyopathy
    Felix W Friedrich
    Institute of Experimental and Clinical Pharmacology and Toxicology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Eur Heart J 30:1648-55. 2009
    ..Calmodulin (CaM) could be of importance given the key role of Ca(2+) for cardiac contractile function and growth. Any variant that affects CaM expression and/or function may impact on FHC clinical expression...
  41. doi request reprint Inhibition of aldehyde dehydrogenase type 2 attenuates vasodilatory action of nitroglycerin in human veins
    Martin W Huellner
    Institute of Experimental and Clinical Pharmacology, University Medical Center Hamburg Eppendorf, Martinistr 52, Hamburg 20246, Germany
    FASEB J 22:2561-8. 2008
    ..In human capacitance vessels, ALDH2 is a key enzyme in the biotransformation of the frequently used antianginal drug nitroglycerin...
  42. ncbi request reprint Atorvastatin desensitizes beta-adrenergic signaling in cardiac myocytes via reduced isoprenylation of G-protein gamma-subunits
    Ulrike Mühlhäuser
    Institute of Experimental and Clinical Pharmacology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    FASEB J 20:785-7. 2006
    ..Taken together, the results of this study show that atorvastatin desensitizes NRCM to beta-adrenergic stimulation by a mechanism that involves reduced isoprenylation of Ggamma and subsequent reductions in the cellular content of Galphas...
  43. pmc Pharmacological characterization of 1-nitrosocyclohexyl acetate, a long-acting nitroxyl donor that shows vasorelaxant and antiaggregatory effects
    Sonia Donzelli
    Department of Experimental Pharmacology and Toxicology, University Medical Center Hamburg Eppendorf, Martinistr 52, D 20246 Hamburg, Germany
    J Pharmacol Exp Ther 344:339-47. 2013
    ..In summary, NCA shows vasoprotective effects and may have a promising profile as a therapeutic agent in vascular dysfunction, warranting further evaluation...
  44. doi request reprint [Vernakalant: a novel antiarrhythmic drug for the rapid conversion of atrial fibrillation to sinus rhythm]
    M N Hirt
    Institut fur Experimentelle und Klinische Pharmakologie, Universitatsklinikum Hamburg Eppendorf, Hamburg
    Dtsch Med Wochenschr 135:971-6. 2010
    ..However, a demonstrated tendency towards proarrhythmia and little experience with this new drug demands precaution even after it has been officially approved...
  45. ncbi request reprint Key role of myosin light chain (MLC) kinase-mediated MLC2a phosphorylation in the alpha 1-adrenergic positive inotropic effect in human atrium
    Michael Grimm
    Institute of Experimental and Clinical Pharmacology, University Hospital Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany
    Cardiovasc Res 65:211-20. 2005
    ..This study investigated alpha(1)-adrenergic contractile effects and the role of MLC kinase (MLCK)-dependent phosphorylation of MLC2 in human atrial muscle strips...
  46. ncbi request reprint Expression of ten RGS proteins in human myocardium: functional characterization of an upregulation of RGS4 in heart failure
    Clemens Mittmann
    Institut fur Experimentelle und Klinische Pharmakologie und Toxikologie, Abteilung für Pharmakologie, Universitatsklinikum Hamburg Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany
    Cardiovasc Res 55:778-86. 2002
    ..We investigated the expression of RGS proteins in the human heart and whether they take part in the pathophysiological changes of heart failure...
  47. doi request reprint Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology
    Thomas Eschenhagen
    Department of Experimental and Clinical Pharmacology and Toxicology, University Medical Center Hamburg Eppendorf, Martinistr 52, D 20246 Hamburg, Germany
    Eur J Heart Fail 13:1-10. 2011
    ....
  48. ncbi request reprint Decreased protein and phosphorylation level of the protein phosphatase inhibitor-1 in failing human hearts
    Ali El-Armouche
    Institute of Experimental and Clinical Pharmacology, University Hospital Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany
    Cardiovasc Res 61:87-93. 2004
    ..It is controversial whether I-1 expression is altered in human heart failure (HF), likely because its detection in heart is difficult due to its low abundance...
  49. ncbi request reprint High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations
    Thomas Rau
    Department of Clinical and Experimental Pharmacology and Toxicology, University Medical Center Hamburg Eppendorf, Hamburg, and Children s Hospital, Friedrich Alexander University Erlangen Nuremberg, Erlangen, Germany
    Clin Pharmacol Ther 80:468-76. 2006
    ..We hypothesized that common genetic variations may contribute to the variability of high-dose methotrexate pharmacokinetics...